Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Crescent Biopharma, Inc. - Common Stock (NQ:CBIO)

20.00 -1.23 (-5.82%)
Streaming Delayed Price Updated: 3:41 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 215,700
Open 21.00
Bid (Size) 19.86 (100)
Ask (Size) 20.06 (400)
Prev. Close 21.23
Today's Range 18.51 - 21.69
52wk Range 8.720 - 27.41
Shares Outstanding 64,532,091
Dividend Yield 2.40%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at May Investor Conferences
From Crescent Biopharma, Inc.
Via GlobeNewswire

Performance

YTD
+80.5%
+80.5%
1 Month
+2.4%
+2.4%
3 Month
+116.6%
+116.6%
6 Month
+54.0%
+54.0%
1 Year
+26.6%
+26.6%

More News

Read More
Which stocks are moving on Friday? ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at March Investor Conferences
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
The Deal That Sent Crescent Biopharma Shares Surging Over 40% Pre-Market Today ↗
Via Stocktwits
News headline image
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
From Crescent Biopharma, Inc.; Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma
Via GlobeNewswire
News headline image
Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From Crescent Biopharma
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at November Investor Conferences
From Crescent Biopharma
Via GlobeNewswire
News headline image
Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
From Crescent Biopharma
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at September Investor Conferences
From Crescent Biopharma
Via GlobeNewswire
News headline image
This Devon Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
Via Benzinga

Frequently Asked Questions

Is Crescent Biopharma, Inc. - Common Stock publicly traded?
Yes, Crescent Biopharma, Inc. - Common Stock is publicly traded.
What exchange does Crescent Biopharma, Inc. - Common Stock trade on?
Crescent Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Crescent Biopharma, Inc. - Common Stock?
The ticker symbol for Crescent Biopharma, Inc. - Common Stock is CBIO on the Nasdaq Stock Market
What is the current price of Crescent Biopharma, Inc. - Common Stock?
The current price of Crescent Biopharma, Inc. - Common Stock is 20.00
When was Crescent Biopharma, Inc. - Common Stock last traded?
The last trade of Crescent Biopharma, Inc. - Common Stock was at 05/15/26 03:41 PM ET
What is the market capitalization of Crescent Biopharma, Inc. - Common Stock?
The market capitalization of Crescent Biopharma, Inc. - Common Stock is 1.29B
How many shares of Crescent Biopharma, Inc. - Common Stock are outstanding?
Crescent Biopharma, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.